Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Can-Fite BioPharma announced that the Australian Patent Office has allowed a patent application covering the use of Namodenoson for treating advanced metastatic cancer. This allowance expands the intellectual property protection for the company's oncology candidate, which is currently in a pivotal Phase 3 trial for advanced hepatocellular carcinoma and a Phase 2a study for pancreatic cancer.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.